Boston Scientific Corp (BSX)vsNexalin Technology Inc. (NXL)
BSX
Boston Scientific Corp
$69.78
+2.39%
HEALTHCARE · Cap: $101.28B
NXL
Nexalin Technology Inc.
$0.40
-2.92%
HEALTHCARE · Cap: $7.57M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 12791591% more annual revenue ($20.07B vs $156,930). BSX leads profitability with a 14.4% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 63/100 (C+).
BSX
Buy63
out of 100
Grade: C+
NXL
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+1.2%
Fair Value
$70.62
Current Price
$69.78
$0.84 discount
Intrinsic value data unavailable for NXL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
15.9% revenue growth
Generating 1.0B in free cash flow
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -1.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bull Case : NXL
The strongest argument for NXL centers on Price/Book.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Bear Case : NXL
The primary concerns for NXL are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
BSX profiles as a growth stock while NXL is a value play — different risk/reward profiles.
NXL carries more volatility with a beta of 4.10 — expect wider price swings.
BSX is growing revenue faster at 15.9% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (63/100 vs 20/100) and 15.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Nexalin Technology Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Nexalin Technology Inc. is a pioneering player in the medical technology sector, specializing in advanced therapies for neurological and psychiatric disorders. The company develops proprietary transcranial electrical stimulation devices that offer non-invasive treatment options for conditions such as anxiety, depression, and substance addiction. With a strong emphasis on cutting-edge research and mental health improvement, Nexalin is positioned to capitalize on the growing demand for innovative healthcare solutions. Its strategic focus on enhancing patient outcomes through technological advancements highlights its potential for substantial growth in the rapidly evolving digital health landscape.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?